Jiangsu Hengrui Medicine Co., Ltd.
600276
Rang in Aktien
#543
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Aktienkurs
$6.89
Marktkapitalisierung
$43.94B
Veränderung (1 Tag)
-2.91%
Veränderung (1 Jahr)
-24.78%
Land
CN
Handel Jiangsu Hengrui Medicine Co., Ltd. (600276)
Kategorie
Healthcare
P/S-Verhältnis für Jiangsu Hengrui Medicine Co., Ltd. (600276)
P/S-Verhältnis zum October 2026 TTM: 9.37
Laut den neuesten Finanzberichten und dem Aktienkurs von Jiangsu Hengrui Medicine Co., Ltd. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 9.37. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 10.39.
P/S-Verlauf für Jiangsu Hengrui Medicine Co., Ltd. von 2001 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 9.37 | -23.96% |
| 2025 | 12.32 | 18.54% |
| 2024 | 10.39 | -17.13% |
| 2023 | 12.54 | 8.76% |
| 2022 | 11.53 | -7.68% |
| 2021 | 12.49 | -41.32% |
| 2020 | 21.29 | 28.72% |
| 2019 | 16.54 | 47.69% |
| 2018 | 11.20 | -3.36% |
| 2017 | 11.59 | 44.55% |
| 2016 | 8.02 | -6.62% |
| 2015 | 8.58 | 63.97% |
| 2014 | 5.24 | -9.71% |
| 2013 | 5.80 | 21.57% |
| 2012 | 4.77 | -5.76% |
| 2011 | 5.06 | -38.70% |
| 2010 | 8.26 | 10.18% |
| 2009 | 7.49 | 29.72% |
| 2008 | 5.78 | -34.42% |
| 2007 | 8.81 | 78.87% |
| 2006 | 4.92 | 420.22% |
| 2005 | 0.95 | 14.31% |
| 2004 | 0.83 | -8.27% |
| 2003 | 0.90 | -28.02% |
| 2002 | 1.25 | -16.11% |
| 2001 | 1.50 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 2.19 | -76.66% |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -24.66% |
IN
|
